Clinical Trials | April 22, 2026
Novo Nordisk’s Etavopivat delivers major Phase 3 win in sickle cell disease
By cutting pain crises & boosting haemoglobin
By cutting pain crises & boosting haemoglobin
It is actually a new ISO Class 5 controlled cleanroom designed to deliver washed, dried, and gamma-sterilized single-use assemblies ready for immediate use.
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Targets high-growth eye care expansion push
Solvents made from renewable feedstocks help reduce reliance on fossil-fuel-based materials
Policy symposium in Hyderabad focuses on life skills education and community?driven solutions
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
The plant is currently scaling towards a production capacity of nearly 3 million gloves per day
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
Subscribe To Our Newsletter & Stay Updated
